SEARCH:   Advanced

Blood, 15 April 2005, Vol. 105, No. 8, pp. 3072-3078. Prepublished online as a Blood First Edition Paper on January 6, 2005; DOI 10.1182/blood-2004-09-3666. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-09-3666v1 105/8/3072    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Asnafi, V. Articles by Dombret, H. Search for Related Content PubMed PubMed Citation Articles by Asnafi, V. Articles by Dombret, H. Related Collections Immunobiology Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study Vahid Asnafi, Agnes Buzyn, Xavier Thomas, Francoise Huguet, Norbert Vey, Jean-Michel Boiron, Oumedaly Reman, Jean-Michel Cayuela, Veronique Lheritier, Jean-Paul Vernant, Denis Fiere, Elizabeth Macintyre, and Hervé Dombret From the Department of Hematology, Necker-Enfants-Malades, Saint Louis, and Pitie-Salpetriere; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Edouard Herriot, Lyon; Hopital Purpan, Toulouse; Institut Paoli Calmettes, Marseille; Hopital du Haut Leveque, Bordeaux; Centre Hospitalier Universitaire, Caen; and INSERM EMIU210, France. Patients with T-cell acute lymphoblastic leukemias (T-ALLs) within the Leucémies Aiguës Lymphoblastiques de l'Adulte-94 (LALA-94) prospective trial were treated with a 4-drug per 4-week induction, with intermediate-dose cytarabine and mitoxantrone salvage treatment for patients not achieving complete remission (CR) in 1 course. Only the latter received allografts, if possible, thus providing an informative setting for assessing early response. Representative patients with T-ALL (91 patients) were classified into surface T-cell receptor (TCR)–expressing T-ALL patients (TCR+ or TCR+), pre- T-ALL patients (cTCR+, TCR–), and immature (IM) cTCR–, TCR– T-ALL patients; 81 patients underwent genotyping for SIL-TAL1, CALM-AF10, HOX11, and HOX11L2. Overall, CR was obtained in 81 (89%) patients; relapse rate was 62% at 4 years and overall survival (OS) rate was 38%. CR rate was significantly lower in IM T-ALL patients after 1 course (45% vs 87%; P < .001) and after salvage (74% vs 97%; P = .002), with the latter inducing a higher rate of CR (9 [64%] of 14) than initial induction. Once CR was obtained, cumulative relapse rates were similar for IM, pre-, and TCR+ T-ALL patients (P = .51), but were higher in HOX11L2 (83%) and SIL-TAL1 (82%) T-ALL patients compared with other genetic subgroups (48%; P = .05). This was associated with an inferior OS for HOX11L2 T-ALLs (13% vs 47% in HOX11L2-T-ALLs; P = .009). The majority of patients with HOX11 T-ALL underwent allografting, predominantly in second CR, but were not associated with a superior OS. Both TCR and genotypic stratification can therefore contribute to risk-adapted management of adult T-ALLs. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: V. Asnafi, A. Buzyn, S. Le Noir, F. Baleydier, A. Simon, K. Beldjord, O. Reman, F. Witz, T. Fagot, E. Tavernier, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study Blood, April 23, 2009; 113(17): 3918 - 3924. [Abstract] [Full Text] [PDF] P. Ballerini, J. Landman-Parker, J. M. Cayuela, V. Asnafi, M. Labopin, V. Gandemer, Y. Perel, G. Michel, T. Leblanc, C. Schmitt, et al. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome Haematologica, November 1, 2008; 93(11): 1658 - 1665. [Abstract] [Full Text] [PDF] F. Baleydier, A.-V. Decouvelaere, J. Bergeron, P. Gaulard, D. Canioni, Y. Bertrand, S. Lepretre, B. Petit, H. Dombret, K. Beldjord, et al. T Cell Receptor Genotyping and HOXA/TLX1 Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome Clin. Cancer Res., February 1, 2008; 14(3): 692 - 700. [Abstract] [Full Text] [PDF] J. Bergeron, E. Clappier, I. Radford, A. Buzyn, C. Millien, G. Soler, P. Ballerini, X. Thomas, J. Soulier, H. Dombret, et al. Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs Blood, October 1, 2007; 110(7): 2324 - 2330. [Abstract] [Full Text] [PDF] C. D. Baldus, T. Burmeister, P. Martus, S. Schwartz, N. Gokbuget, C. D. Bloomfield, D. Hoelzer, E. Thiel, and W. K. Hofmann High Expression of the ETS Transcription Factor ERG Predicts Adverse Outcome in Acute T-Lymphoblastic Leukemia in Adults J. Clin. Oncol., October 10, 2006; 24(29): 4714 - 4720. [Abstract] [Full Text] [PDF] B. Burkhardt, W. Woessmann, M. Zimmermann, U. Kontny, J. Vormoor, W. Doerffel, G. Mann, G. Henze, F. Niggli, W.-D. Ludwig, et al. Impact of Cranial Radiotherapy on Central Nervous System Prophylaxis in Children and Adolescents With Central Nervous System-Negative Stage III or IV Lymphoblastic Lymphoma J. Clin. Oncol., January 20, 2006; 24(3): 491 - 499. [Abstract] [Full Text] [PDF] N. Gokbuget and D. Hoelzer Treatment of Adult Acute Lymphoblastic Leukemia Hematology, January 1, 2006; 2006(1): 133 - 141. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020